Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc (OTCQX:ANPCY) announced significant business progress and an unaudited trading update for 2022, marking it as a breakthrough year with FDA clearance for its Parsortix cancer cell harvesting system. Key highlights include sensitivity and specificity results of 90% and 93%, respectively, in ovarian cancer studies. The company raised £20.1 million to support commercialization despite challenging market conditions. While 2022 revenue is anticipated just above £1 million and an operating loss of £22 million, angling for strong growth in 2023 remains a focus with a pipeline of new orders and partnerships.
ANGLE plc presented two posters at the San Antonio Breast Cancer Symposium 2022, showcasing the Parsortix PC1 Clinical System's ability to isolate circulating tumor cells (CTCs) from metastatic breast cancer patients. The studies involved 75 MBC patients and 71 healthy controls, demonstrating successful CTC capture through cytological and molecular evaluations. Key findings included the identification of CTCs in over 45% of MBC patients, with significant expression of CTC-related genes. This data supports the FDA classification of Parsortix as a Class II device, which is expected to drive commercial success.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced the issuance of 56,666 new ordinary shares due to the exercise of employee options. This will bring the total number of ordinary shares to 260,580,547, effective from December 7, 2022. The new shares rank equally with existing shares and have been submitted for trading on AIM. This issuance is part of the company's ongoing strategy to incentivize employees. The announcement also emphasizes the company's advancements in liquid biopsy technology, specifically through its FDA-cleared Parsortix system for capturing circulating tumor cells.
ANGLE plc has announced successful results from a multi-centre clinical study utilizing its Parsortix system to enrich circulating tumor cells (CTCs) from 207 metastatic breast cancer patients. The study demonstrated that CTCs could be analyzed using various downstream techniques, providing data for the successful De Novo FDA clearance of the Parsortix system on May 24, 2022. Notably, CTCs were detected in 48.5% of samples, highlighting the system's clinical utility for treatment monitoring and selection.
ANGLE plc presented its study at the International Society of Liquid Biopsy meeting, demonstrating the simultaneous analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a single blood sample. The proof of concept study confirmed that isolating CTCs does not compromise ctDNA quality, adding significant value for cancer characterization and patient monitoring. This multimodal approach enhances precision medicine by allowing genetic, transcriptional, and protein-level insights, positioning ANGLE competitively in an expanding liquid biopsy market.
ANGLE plc, a leading liquid biopsy company, has announced the issuance of 25,000 new ordinary shares following the exercise of employee options. The new shares will rank equally with existing shares, raising the total number of ordinary shares to 260,523,881. The shares are expected to be admitted for trading on AIM on October 27, 2022. This move aims to enhance liquidity and shareholder participation while aligning employee interests with company performance.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced the closure of its Toronto operations to streamline costs, saving approximately £2.6 million in 2023 and £4.0 million annually thereafter. The decision follows increasing operational costs in Canada due to currency fluctuations and changes in UK R&D tax credit rules, making UK-based operations more cost-effective. ANGLE plans to centralize R&D in Guildford, UK, without significant impact on ongoing operations. A one-off closure cost of £0.5 million is expected, but the move extends the company's cash runway into H2 2024.
On October 14, 2022, ANGLE plc announced a TR-1 notification revealing a change in voting rights as Aegon NV crossed a key threshold. As of October 12, Aegon holds 3.77% of voting rights attached to shares and 0.22% through financial instruments, totaling 3.99%. This marks a slight decrease from the previous position of 4.02%. The information indicates increased scrutiny of significant shareholders and their influence on company governance.
ANGLE plc (OTCQX:ANPCY) has entered a distribution agreement with Promedeus to roll out the Parsortix system in the Czech Republic, targeting metastatic breast cancer. This partnership capitalizes on Promedeus's experience in advanced medical equipment distribution and oncology sector knowledge. The Parsortix system, which is FDA cleared and CE marked, enables non-invasive harvesting of circulating tumor cells from blood. ANGLE anticipates similar deals in other territories as it expands its market presence.
ANGLE plc announced a significant change in its share ownership as a major stakeholder, Aegon NV, crossed the voting rights threshold of 3.80% on September 28, 2022. This acquisition increases Aegon's holdings to a total of 10,467,539 voting rights, reflecting 4.02% when considering voting rights from financial instruments. The notification was filed with the relevant authorities on September 29, 2022.
FAQ
What is the current stock price of CELLBXHEALTH PLC (ANPCY)?
What is the market cap of CELLBXHEALTH PLC (ANPCY)?
